Lupuzor: Completed Ph III enrollment

ImmuPharma completed enrollment of 200 patients in a double-blind, placebo-controlled, international Phase III trial evaluating 200 ug subcutaneous Lupuzor every 4 weeks plus standard of care (SOC) fo...